Business
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the \"Study\").This Study is the only study carried out anywhere in the world today, to evaluate the relative performance of liraglutide processed with DehydraTECH. In humans, semaglutide has been shown in other studies to be more than twice as effective at promoting weight loss as liraglutide. Thus, the continued outperformance of DehydraTECH-liraglutide compared to DehydraTECH-semaglutide is of particular interest. In this Study, the liraglutide in Study group H was administered orally even though it is injected when used by patients under the brand names Saxenda® or Victoza®.Animal Weights (grams)DehydraTECH GroupsEnd of Acclimation PeriodDay 28% Change to Day 28Day 56% Change to Day 56A: CBD1427.9432.6+1.10%438.0+2.36%B: CBD2394.6393.3-0.33%386.1-2.15%C: CBD3416.0408.8-1.72%407.3-2.08%D: CBD4431.2431.7+0.11%434.2+0.69%E: Rybelsus1w/SNAC394.9394.6-0.06%401.4+1.65%F: Rybelsus2w/SNAC406.2409.1+0.70%406.7+0.11%G: SemaglutideNo SNAC394.2394.8+0.15%399+1.21%H: LiraglutideNo SNAC392.2385.7-1.65%373.6-4.74%Average407.1406.3-0.21%405.8-0.37%Notes- Groups A through D were different DehydraTECH-CBD compositions- Groups E and F were reformulated Rybelsus DehydraTECH compositions- Groups G and H used pure GLP-1 drugs (semaglutide and liraglutide respectively) in DehydraTECH compositions- Recalculations led to slight changes from earlier reported dataFor context, in Lexaria's diabetic animal study DIAB-A22-1 reported on March 2, 2023, the obese control group of animals that received no treatment, experienced 3.04% weight gain during the first 28 days of that study.DehydraTECH-CBD groups B and C are also outperforming all of the Rybelsus® and semaglutide DehydraTECH composition groups regardless of whether the semaglutide has or has not been processed with the salcaprozate sodium technology known as \"SNAC\". Lexaria is strongly encouraged by the robust performance achieved so far from its Deh...